

# Frostbite Interventions

## THOR Conference 2024

Rachel Nygaard, PhD  
Department of Surgery  
Hennepin County Medical Center  
Minneapolis, MN USA



[www.HennepinTrauma.org](http://www.HennepinTrauma.org)  
[www.RachelNygaard.com](http://www.RachelNygaard.com)



@HennepinTrauma  
@RachelNygaard

# Disclosure

- Eicos Sciences – scientific consulting/writing – ended
- Triton Systems – scientific consulting - ended
  
- Discussing off-label use of thrombolytics




# Objectives

- Understanding frostbite
- Interventions
- Going forward

# Abbreviations & definitions


- tPA -> thrombolytics
- Rapid rewarming -> warming frozen extremity in (circulating) warm water (35-39C)

# Frostbite impact on the military



- Armed Forces Health Surveillance Division. Cold Weather Injuries Among the Active and Reserve Components of the U.S. Armed Forces, July 2018-June 2023. *MSMR*. 2023 Nov 20;30(11):2-11. PMID: 38051632.
- Armed Forces Health Surveillance Division. Update: Cold Weather Injuries, Active and Reserve Components, U.S. Armed Forces, July 2015-June 2020. *MSMR*. 2020 Nov;27(11):15-24.
- Endorf FW, Nygaard RM. Social Determinants of Poor Outcomes Following Frostbite Injury: A Study of the National Inpatient Sample. *J Burn Care Res*. 2021 Nov 24;42(6):1261-1265.

# Frostbite impact on the military



|       | US Armed Forces | HCMC | HCMC |
|-------|-----------------|------|------|
| 18-19 | 257             | 551  | 71   |
| 19-20 | 195             | 317  | 85   |
| 20-21 | 296             | 514  | 41   |
| 21-22 | 287             | 928  | 62   |
| 22-23 | 202             | 759  | 96   |

| Degree | 1 <sup>st</sup> - 4 <sup>th</sup> | Encounters<br>1 <sup>st</sup> - 4 <sup>th</sup> | 3 <sup>rd</sup> - 4 <sup>th</sup> |
|--------|-----------------------------------|---|-----------------------------------|
|--------|-----------------------------------|---|-----------------------------------|

- Modified from: Armed Forces Health Surveillance Division. Cold Weather Injuries Among the Active and Reserve Components of the U.S. Armed Forces, July 2018-June 2023. MSMR. 2023 Nov 20;30(11):2-11. PMID: 38051632.
- Modified from: Endorf FW, Nygaard RM. Social Determinants of Poor Outcomes Following Frostbite Injury: A Study of the National Inpatient Sample. J Burn Care Res. 2021 Nov 24;42(6):1261-1265.

# Frostbite impact on the military


Systematic review

## Frostbite: a systematic review on freezing cold injuries in a military environment

T T C F van Dongen ,<sup>1,2</sup> R R Berendsen,<sup>3</sup> F J M de Jong,<sup>4</sup> E L Endert,<sup>4</sup>  
R A van Hulst,<sup>5</sup> R Hoencamp<sup>1,2,6,7</sup>

Most soldiers (50-89%) could not fully return to duty or were discharged


# Freezing Cold Injury (FCI/frostbite)










# Pathophysiology of Severe Frostbite

- Initial Injury:
  - Ice crystal formation inside cells causes mechanical disruption and cell death.
- Vascular Changes:
  - Vasoconstriction reduces blood flow, causing ischemia and tissue necrosis.
- Rewarming Damage:
  - Reperfusion after rewarming leads to oxidative stress, inflammation, and edema.



Gao Y, Wang F, Zhou W, Pan S. Research progress in the pathogenic mechanisms and imaging of severe frostbite. *Eur J Radiol.* 2021 Apr;137:109605. doi: 10.1016/j.ejrad.2021.109605  
Zafren, K. (2014). Frostbite: prevention and initial management. *High Altitude Medicine & Biology*, 15(2), 148-155.

## The classification of freezing cold injuries - a NATO research task group position paper

Arne Johan Norheim <sup>a</sup>, Wendy Sullivan-Kwantes <sup>c</sup>, Tuva Steinberg <sup>a,b</sup>, John Castellani <sup>d</sup>  
and Karl E. Friedl <sup>d</sup>









<sup>a</sup>National Research Center in Complementary and Alternative Medicine (NAFKAM), Institute of Community Medicine, UiT- The Arctic University of Norway, Tromsø, Norway; <sup>b</sup>Norwegian Armed Forces - Joint Medical Service, Norway; <sup>c</sup>Joint medical services, Defence Research and Development Canada-Toronto Research Center, Sessvollmoen; <sup>d</sup>U.S. Army Research Institute of Environmental Medicine, Natick MA USA

Scores based on Injury/Symptoms  
(i.e. Superficial/Severe or Degree)

≠



Outcome Grade  
(Cauchy Frostbite Grade)

### Grading severity of frostbite after rewarming

| Absence of cyanosis  | Cyanosis on distal phalanx   | Cyanosis up to MP joint  | Cyanosis proximal to MP joint  |
|--|--|--|--|
|   |   |   |   |
|  |  |  |  |
| Grade 1<br>No amputation of bone   | Grade 2<br>Moderate risk of amputation   | Grade 3<br>High risk of amputation   | Grade 4<br>Risk of amputation 100%   |

Cauchy et al. 2016

# Visual Assessment of Severity Lack Reliability



No significant correlations were found between amputation level and clinical assessment

- admission ( $r = -0.08$ ,  $p = 0.729$ )
- day 3 ( $r = 0.18$ ,  $p = 0.459$ )
- discharge ( $r = 0.26$ ,  $p = 0.260$ ).

ORIGINAL RESEARCH

## Retrospective study of 70 cases of severe frostbite lesions: a proposed new classification scheme

EMMANUEL CAUCHY, MD; ERIC CHETAÏLLE, MD; VINCENT MARCHAND, MD;  
BERNARD MARSIGNY, MD

*From the Department of Mountain Medicine and Trauma, Chamonix Hospital, Chamonix, France.*

### THE INITIAL LESION




The initial lesion at hospitalization was characterized by cyanosis and grayness in color, which extended from the digit tip in a centripetal, ascending character toward the base of the limb. This aspect persisted despite rapid re-warming and was accompanied by anesthesia. In the study group, there were no blisters within 12 hours of beginning rewarming, except in 1 case with associated skin trauma (related to use of the hands to build a snow cave). For a few cases, the lesion was more heterogeneous with associated edema. The limit of the initial lesion was usually quite well demarcated just after initial treatment.

**Table 1.** Probability of amputation based on the extent of the initial lesion

|               | <i>Extent<br/>(level of<br/>involvement)</i> | <i>Probability<br/>of bone<br/>amputation<br/>(95% CI)</i> |
|---------------|--|--|
| Hand          | 5 (carpal/tarsal)                            | 100  |
|               | 4 (metacarpal/metatarsal)                    | 100  |
|               | 3 (proximal phalanx)                         | 83 (66; 100)   |
|               | 2 (intermediary phalanx)                     | 39 (25; 52)  |
|               | 1 (distal phalanx)                           | 1 (00; 03)   |
| Foot          | 5 (carpal/tarsal)                            | 100  |
|               | 4 (metacarpal/metatarsal)                    | 98 (93; 100)   |
|               | 3 (proximal phalanx)                         | 60 (45; 74)  |
|               | 2 (intermediary phalanx)                     | 23 (10; 35)  |
|               | 1 (distal phalanx)                           | 0  |
| Hand and foot | 5 (carpal/tarsal)                            | 100  |
|               | 4 (metacarpal/metatarsal)                    | 98 (95; 100)   |
|               | 3 (proximal phalanx)                         | 67 (55; 79)  |
|               | 2 (intermediary phalanx)                     | 31 (22; 41)  |
|               | 1 (distal phalanx)                           | 1 (00; 02)   |

Specificity ~ 30%

No correlation of treatment with final amputation



|                   |                                      |                           |                       |                       |          |
|-------------------|--------------------------------------|---------------------------|-----------------------|-----------------------|----------|
| Pulses            | Present                              | Reduced                   | Absent                | Absent                |          |
| Perfusion Imaging | Present                              | Variable                  | Reduced to Absent     | Absent                |          |
| Color*            | Darkened/reddish skin, white patches | Discolored skin           | Bluish/white          | Bluish/black          | Necrosis |
| Blister**         | No blisters                          | Blisters with clear fluid | Clear and Hemorrhagic | Clear and Hemorrhagic |          |
| Lesion**          | No lesions                           | Present                   | Present               | Present               |          |
| Sensation/Pain*** | Intense                              | Reduced                   | Absent                | Absent                |          |

Cauchy

Grade 1

Grade 2

Grade 3

Grade 4

Degree

1st

2nd

3rd

4th

Superficial


Severe

\* Melanin level in skin will impact visual appearance

\*\*Blisters/Lesions may not be present immediately after rewarming

\*\*\*Rewarming is very painful, sensation is absent in areas of severe frostbite injury.

Surrounding tissue typically has partial thickness injuries (lessor grade/severity more proximal)



**Figure 1:** Yukon Frostbite Protocol. Note: PTT = partial thromboplastin time.




*Specific Aim 2: To assess the utility and accuracy of visual assessment of frostbite injury compared to formal perfusion imaging and outcome*

# Intervention Goals


- Primary Goals:
  - Prevent tissue ischemia.
  - Mitigate inflammation.
  - Restore circulation and protect tissue.
- Interventions Overview:
  - Thrombolytics
  - Iloprost
  - Anti-thrombotics (anti-coags/anti-platelets)
  - Anti-inflammatory (ibuprofen)





# Thrombolytics – Tissue Plasminogen Activator (tPA)

- Effect: Breaks down blood clots in frostbite-affected tissues, restoring blood flow and oxygen delivery to the extremities.
- Clinical Impact:
  - Shown to significantly reduce amputation rates when used within 24 hours.



Bhattacharjee, Payel, and Debasish Bhattacharyya. "An insight into the abnormal fibrin clots—its pathophysiological roles." *Fibrinolysis and Thrombolysis* (2014): 1-29.

Summary patients treated with and without thrombolytics and resulting salvage rate

| Author       | Year | Total Number of Patients | Number of Patients |                |       | Imaging     | Digit, segment, or overall Salvage tPA* | Weighted Averages tPA | Digit, segment, or overall Salvage no tPA/adjuvant therapy alone* |
|--------------|------|--------------------------|--------------------|----------------|-------|-------------|---|-----------------------|---|
|              |      |                          | Treated with tPA   | Delivery Route |       |             |   |                       |   |
| Twomey       | 2005 | 6                        | 6                  | IA             | Angio | 50          |   | -                     |   |
| Bruen        | 2007 | 32                       | 6                  | IA             | Angio | 90          |   | 49                    |   |
| Taveri       | 2016 | 13                       | 6                  | IA             | Angio | 83          |   | -                     |   |
| Gonzaga      | 2016 | 69                       | 6                  | IA             | Angio | 68.6        |   | unk                   |   |
| Linford      | 2017 | 14                       | 6                  | IA             | Angio | 81.1        |   | unk                   |   |
| Patel        | 2017 | 17                       | 6                  | IA             | Angio | 85          |   | 23                    |   |
| Al Yafi      | 2019 | 18                       | 6                  | IA             | Angio | 44.4        |   | 33.3                  |   |
| Paine        | 2020 | 17                       | 6                  | IA             | Angio | 80          |   | unk                   |   |
| Heard        | 2020 | 99                       | 6                  | IA             | Angio | 82          |   | 64.3                  |   |
| Heard        | 2020 | 3                        | 0                  | IV             | None  | 100         |   | -                     |   |
| Twomey       | 2005 | 13                       | 0                  | IV             | None  | 81          |   | -                     |   |
| Cauchy       | 2011 | 47                       | 0                  | IV             | None  | 96.9        |   | -                     |   |
| Johnson      | 2011 | 11                       | 0                  | IV             | None  | 60.9        |   | -                     |   |
| Jones        | 2017 | 15                       | 0                  | IV             | None  | 72.5        |   | unk                   |   |
| Nygaard      | 2017 | 73                       | 0                  | IV             | None  | 74          |   | 55                    |   |
| Wexler       | 2017 | 6                        | 0                  | IV             | None  | 75.4        |   | -                     |   |
| Lacey        | 2021 | 165                      | 0                  | IV             | None  | 84.6        |   | 54.3                  |   |
| Carmichael   | 2021 | 199                      | 0                  | IV             | None  | 68.1        |   | 59.8                  |   |
| Poole**      | 2021 | 22                       | 5                  | IV+iloprost    | None  | 50          |   | -                     |   |
| <b>IA</b>    |      | <b>285</b>               | <b>125</b>         |                |       | <b>73.8</b> | <b>76.7</b>                             |                       |   |
| <b>IV</b>    |      | <b>532</b>               | <b>302</b>         |                |       | <b>79.3</b> | <b>77.1</b>                             |                       |   |
| <b>Total</b> |      | <b>817</b>               | <b>427</b>         |                |       | <b>76.5</b> | <b>77</b>                               | <b>46.5</b>           |   |


**Amputation Rate**  
**23% tPA**  
**54% no tPA**

Abbreviations: h, hours; IA, intra-arterial; IV, intravascular; tPA, thrombolytics; unk, unknown.

Summary patients treated with and without thrombolytics and resulting salvage rate

| Author       | Year | Number of Patients |              | Thrombolysis | Salvage       | Digit, segment, or overall | Weighted     | Digit, segment, or overall Salvage |
|--------------|------|--------------------|--------------|--------------|---------------|----------------------------|--------------|------------------------------------|
|              |      | Total Number       | Treated with |              |               | Salvage tPA*               | Averages tPA | no tPA/adjuvant therapy alone*     |
| Twomey       |      |                    |              |              |               | 50                         |              | -                                  |
| Bruen        |      |                    |              |              |               | 90                         |              | 49                                 |
| Taveri       |      |                    |              |              |               | 83                         |              | -                                  |
| Gonzaga      |      |                    |              |              |               | 68.6                       |              | unk                                |
| Linford      |      |                    |              |              |               | 81.1                       |              | unk                                |
| Patel        |      |                    |              |              |               | 85                         |              | 23                                 |
| Al Yafi      |      |                    |              |              |               | 44.4                       |              | 33.3                               |
| Paine        |      |                    |              |              |               | 80                         |              | unk                                |
| Heard        |      |                    |              |              |               | 82                         |              | 64.3                               |
| Heard        |      |                    |              |              |               | 100                        |              | -                                  |
| Twomey       |      |                    |              |              |               | 81                         |              | -                                  |
| Cauchy       |      |                    |              |              |               | 96.9                       |              | -                                  |
| Johnson      | 2011 | 11                 | 11           | IV           | Tc99          | 60.9                       |              | -                                  |
| Jones        | 2017 | 15                 | 12           | IV           | Tc99          | 72.5                       |              | unk                                |
| Nygaard      | 2017 | 73                 | 45           | IV           | Tc99          | 74                         |              | 55                                 |
| Wexler       | 2017 | 6                  | 6            | IV           | None          | 75.4                       |              | -                                  |
| Lacey        | 2021 | 165                | 125          | IV           | Tc99 & M      | 84.6                       |              | 54.3                               |
| Carmichael   | 2021 | 199                | 72           | IV           | Visual & Tc99 | 68.1                       |              | 59.8                               |
| Poole**      | 2021 | 22                 | 5            | IV+iloprost  | None          | 50                         |              | -                                  |
| <b>IA</b>    |      | <b>285</b>         | <b>125</b>   |              |               | <b>73.8</b>                | <b>76.7</b>  |                                    |
| <b>IV</b>    |      | <b>532</b>         | <b>302</b>   |              |               | <b>79.3</b>                | <b>77.1</b>  |                                    |
| <b>Total</b> |      | <b>817</b>         | <b>427</b>   |              |               | <b>76.5</b>                | <b>77</b>    | <b>46.5</b>                        |

**Amputation Rate**  
 IA 23.3%  
 IV 22.9%



Abbreviations: h, hours; IA, intra-arterial; IV, intravascular; tPA, thrombolytics; unk, unknown.


# Time Is Tissue

- Every hour delay 28% decrease in salvage
- Remote Thrombolytic Role
  - 2.3% complication (N=2)
  - Efficacious (OR 0.19, 0.05-0.65)
- Earlier delivery -> better outcomes

## Guidelines for Thrombolytic Therapy for Frostbite

Sean Hickey<sup>\*</sup>, Amy Whitson<sup>†</sup>, Larry Jones<sup>†</sup>, Lucy Wibbenmeyer<sup>†</sup>, Colleen Ryan<sup>||</sup>, Ryan Fey<sup>S</sup>, Jeffrey Litt<sup>‡</sup>, Renata Fabia<sup>\*\*</sup>, Lee Cancio<sup>††</sup>, William Mohr<sup>††,|||</sup>, John Twomey<sup>SS</sup>, Anne Wagner<sup>††</sup>, Amalia Cochran<sup>†,◊</sup>, J. Kevin Bailey<sup>\*\*\*,◊</sup>


The data are insufficient to support standardized treatment of all patients with frostbite with thrombolytic therapy. The following guidelines, however, should be applied to all patients with cyanosis proximal to the distal phalanx (Grade 3 or 4 frostbite injury) and demonstrated loss of perfusion at or proximal to the middle phalanx immediately after rewarming.




Nygaard RM, Lacey AM, Lemere A, Dole M, Gayken JR, Lambert Wagner AL, Fey RM. Time Matters in Severe Frostbite: Assessment of Limb/Digit Salvage on the Individual Patient Level. J Burn Care Res. 2017  
Carmichael H, Michel S, Smith TM, Duffy PS, Wiktor AJ, Lambert Wagner A. Remote Delivery of Thrombolytics Prior to Transfer to a Regional Burn Center for Tissue Salvage in Frostbite: A Single-center Experience of 199 Patients. J Burn Care Res. 2022

# Time Is Tissue, but


...treatment can be effective out to a wider range of times.



# Bleeding complications in severe frostbite




|        | Category 0 | Category 1 | Category 2 | Category 3 |
|--------|------------|------------|------------|------------|
| No tPA | 40 (88.9)  | 3 (6.7)    | 0 (0)      | 2 (4.4)    |
| tPA    | 91 (63.6)  | 33 (23.1)  | 9 (6.3)    | 10 (7.0)   |



# Vasodilators – Iloprost

- Mechanism of Action:  
Iloprost is a prostacyclin analog that acts on prostaglandin I<sub>2</sub> (PGI<sub>2</sub>) receptors

- inhibits platelet aggregation and causes vasodilation



**Figure 1.** Conversion of arachidonic acid to thromboxane and prostaglandins and their known analogues, inhibitors and roles (adapted from references 8, 22, 23 and 24).



## Iloprost for the treatment of frostbite: a scoping review

Josianne Gauthier<sup>a</sup>, Dunavan Morris-Janzen<sup>b</sup> and Alexander Poole<sup>a,c</sup>

<sup>a</sup>Whitehorse General Hospital, Yukon Hospital Corporation, Whitehorse, Yukon, Canada; <sup>b</sup>Northern Medical Program, University of British Columbia, Prince George, British Columbia, Canada; <sup>c</sup>Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

**Table 1.** Overall characteristics of included studies.

| Included Study                              | Country             | Study Design                                   | Number of patients treated with iloprost | Percentage of male patients | Patient age, mean | Predisposing event  | Frostbite severity      | Number of digits affected |
|---|---------------------|--|--|-----------------------------|-------------------|---|-------------------------|---------------------------|
| Groechenig <b>1994</b> [21]                 | Austria             | Case report                                    | 5  | 80%                         | 35                | Sport, substance use, paralysis                               | 2nd and 3rd degree      | -                         |
| Hödl <b>2005</b> [38] [German]              | Austria             | Case report                                    | 2  | 100%                        | 37                | Sport   | 1st, 2nd and 3rd degree | 20                        |
| Roche-Nagle et al. <b>2008</b> [39]         | Ireland             | Case report                                    | 1  | 100%                        | 47                | Homelessness, substance use                                   | Severe                  | 10                        |
| Imray et al. <b>2009</b> [40]               | England             | Case report                                    | 1  | -                           | n/a               | Sport   | -                       | 8                         |
| Cauchy et al. <b>2011</b> [41]              | France              | Randomised controlled trial                    | 32                                       | 100%                        | 32                | Sport   | Stage 2–4               | 301                       |
| Gorjanc et al. <b>2012</b> [42] [Slovenian] | Slovenia            | Case series                                    | 7  | -                           | n/a               | Sport   | Deep                    | -                         |
| Haik J et al. <b>2016</b> [43]              | Nepal, Israel       | Case series                                    | 4  | 75%                         | 30                | Sport   | Grade 1–4               | -                         |
| Cauchy et al. <b>2016</b> [44] (Abstract)   | France              | Case series (iloprost versus other therapies)  | 78                                       | -                           | -                 | -   | Grade 2–4               | -                         |
| Poole & Gauthier <b>2016</b> [45]           | Canada              | Case report                                    | 2  | 100%                        | 45                | Sport   | Grade 3                 | 10                        |
| Lindford et al. <b>2017</b> [46]            | Finland             | Case series                                    | 4  | -                           | -                 | n/a   | Severe                  | n/a                       |
| Pandey et al. <b>2018</b> [47]              | Nepal               | Case series                                    | 5  | 100%                        | 39                | Sport   | Grade 2–4               | 34                        |
| Gorjanc et al. <b>2018</b> [48] (Abstract)  | Slovenia            | Case report                                    | 2  | 100%                        | 25                | Sport   | Deep                    | -                         |
| Irrarrazaval et al. <b>2018</b> [49]        | Nepal               | Case report                                    | 1  | 100%                        | 60                | Sport   | Grade 2 and 3           | 5                         |
| Jud et al. <b>2019</b> [50]                 | Austria             | Case report                                    | 1  | 100%                        | 45                | Sport   | Grade 2                 | -                         |
| Lorenzo-Villalba et al. <b>2021</b> [51]    | France              | Case report                                    | 1  | 0%                          | 83                | Chronic disease (Cold Agglutinin Disease)                     | -                       | -                         |
| Poole et al. <b>2021</b> [52]               | Canada              | Case series                                    | 22                                       | 77%                         | 39                | Sport, substance use, car trouble, work, psychiatric disorder | Grade 2–4               | 142                       |
| MacLennan et al. <b>2021</b> [53]           | Canada              | Case report                                    | 1  | 100%                        | 48                | Car trouble   | Grade 2                 | 1                         |
| Magnan et al. <b>2021</b> [54]              | Switzerland, France | Prospective single-arm study                   | 58                                       | 93%                         | 33                | Sport, work, homelessness                                     | Grade 3 and 4           | 238                       |
| Magnan et al. <b>2022</b> [55]              | Switzerland         | Case report                                    | 1  | 100%                        | 36                | Sport   | Grade 3                 | 10                        |
| Crooks et al. <b>2022</b> [56]              | Canada              | Case series (iloprost versus standard of care) | 26                                       | 89%                         | 36                | Substance use, car trouble, work, sport, unknown              | Grade 2–4               | 242                       |
| <b>All studies</b>                          | n/a                 | n/a  | <b>254</b>                               | <b>88%</b>                  | <b>42</b>         | n/a   | n/a                     | <b>&gt;1000</b>           |

“-”= information not available, “n/a”= not applicable.

Table 3. Relevant outcome data extracted.

| Included Study                    | Outcome measured   | Outcome  | Adverse drug event  |
|-----------------------------------|--|--|---|
| Groechenig 1994 [21]              | Patients requiring amputation  | 0/5 (0%)   | -   |
| Hödl 2005 [38]                    | Affected digits requiring amputation   | 5/20 (25%)   | None  |
| Roche-Nagle et al. 2008 [39]      | Affected limbs requiring amputation  | 2/2 (100%)   | -   |
| Imray et al. 2009 [40]            | Affected digits appearance and function  | Full function regained                                 | -   |
| Cauchy et al. 2011 [41]           | Risk of patient requiring amputation based on bone scan at day 8                               | 0/16 (0%) iloprost<br>3/16 (19%) iloprost + alteplase  | Hot flashes (55%), nausea (25%), palpitation (15%), vomiting (5%)   |
|                                   | Affected digits requiring amputation according to treatment                                    | 0/142 (0%) iloprost<br>5/159 (3%) iloprost + alteplase |   |
|                                   | Affected digits requiring amputation according to severity of frostbite                        | Stage 2<br>0/64 (0%)                                   | Stage 3<br>0/74 (0%)  |
|                                   |  | Stage 4<br>0/2 (0%)                                    | iloprost  |
|                                   | Affected digits requiring amputation according to time   |  |   |
| Gorjanc et al. 2012 [42]          | Patients requiring amputation  |  | Dizziness and hypotension requiring discontinuation of iloprost (29%)   |
| Haik J et al. 2016 [43]           | Patients requiring amputation  |  | -   |
| Cauchy et al. 2016 [44]           | Patients requiring amputation according to severity of frostbite                               |  | -   |
| Poole & Gauthier 2016 [45]        | Affected digits requiring amputation   |  | None  |
| Lindford et al. 2017 [46]         | Overall digital salvage  |  | None  |
| Pandey et al. 2018 [47]           | Affected digits requiring amputation   |  | Headache (40%), nausea (40%), hypotension requiring dose reduction (20%)  |
| Gorjanc et al. 2018 [48]          | n/a  |  | -   |
| Irrarazaval et al. 2018 [49]      | Affected digits requiring amputation   |  | -   |
| Jud et al. 2019 [50]              | Patient requiring amputation   |  | -   |
| Lorenzo-Villalba et al. 2021 [51] | Affected limbs requiring amputation  |  | Hypotension and headache limiting dose increase (100%)  |
| Poole et al. 2021 [52]            | Patients requiring amputation  |  | Headache (50%), flushing (36%), tachycardia (36%), nausea (27%), vomiting (9%), dizziness (9%), hypotension (4%), bleeding (4%) |
| MacLennan et al. 2021 [53]        | Visual microvascular flow and treatment response   |  | None  |
| Magnan et al. 2021 [54]           | Preserved segment (mean) compared to amputated rays***   |  | -   |
| Magnan et al. 2022 [55]           | Affected digits requiring amputation   | 2 iloprost alone<br>0/10 (0%)                          | -   |
| Crooks et al. 2022 [56]           | Affected digits requiring amputation according to frostbite severity compared to standard care | Grade 2<br>0/44 (0%)                                   | Tachycardia requiring dose reduction (12%), headache (8%), headache requiring iloprost discontinuation (4%)                     |
|                                   |  | Grade 3<br>18/102 (18%)                                |   |
|                                   |  | Grade 4<br>44/96 (46%)                                 |   |

Overall amputation rate following iloprost ranges from 0-100%, but most showed improvement

“.“ = information not available

\* Calculated using the total number of digits at risk minus number of digits amputated divided by total number of digits at risk multiplied by 100

\*\* Each phalanx and each metacarpal or metatarsal is defined as a segment. Preserved segments was defined as the difference between the number of segments with frostbite and lost segments

\*\*\* 4 segments comprise a ray (3 segments for the thumb or the hallux)

Table 3. Relevant outcome data extracted.

| Included Study                    | Outcome measured   | Outcome   | Adverse drug event  |
|-----------------------------------|--|---|---|
| Groechenig 1994 [21]              | Patients requiring amputation  | 0/5 (0%)  | -   |
| Hödl 2005 [38]                    | Affected digits requiring amputation   | 5/20 (25%)  | None  |
| Roche-Nagle et al. 2008 [39]      | Affected limbs requiring amputation  | 2/2 (100%)  | -   |
| Imray et al. 2009 [40]            | Affected digits appearance and function  | Full function regained  | -   |
| Cauchy et al. 2011 [41]           | Risk of patient requiring amputation based on bone scan at day 8                               | 0/16 (0%) iloprost<br>3/16 (19%) iloprost + alteplase                     | Hot flashes (55%), nausea (25%), palpitation (15%), vomiting (5%)   |
|                                   | Affected digits requiring amputation according to treatment                                    | 0/142 (0%) iloprost<br>5/159 (3%) iloprost + alteplase                    |   |
|                                   | Affected digits requiring amputation according to severity                                     | Stage 2    Stage 3    Stage 4   |   |
|                                   | Affected digits requiring amputation according to time   |   |   |
| Gojanc et al. 2012 [42]           | Patients requiring amputation  |   | Dizziness and hypotension requiring discontinuation of iloprost (29%)   |
| Haik J et al. 2016 [43]           | Patients requiring amputation  |   | -   |
| Cauchy et al. 2016 [44]           | Patients requiring amputation according to severity  |   | -   |
| Poole & Gauthier 2016 [45]        | Affected digits requiring amputation   |   | None  |
| Lindford et al. 2017 [46]         | Overall digital salvage  |   | None  |
| Pandey et al. 2018 [47]           | Affected digits requiring amputation   |   | Headache (40%), nausea (40%), hypotension requiring dose reduction (20%)  |
| Gojanc et al. 2018 [48]           | n/a  |   | -   |
| Irrarazaval et al. 2018 [49]      | Affected digits requiring amputation   |   | -   |
| Jud et al. 2019 [50]              | Patient requiring amputation   |   | -   |
| Lorenzo-Villalba et al. 2021 [51] | Affected limbs requiring amputation  |   | Hypotension and headache limiting dose increase (100%)  |
| Poole et al. 2021 [52]            | Patients requiring amputation  |   | Headache (50%), flushing (36%), tachycardia (36%), nausea (27%), vomiting (9%), dizziness (9%), hypotension (4%), bleeding (4%) |
| MacLennan et al. 2021 [53]        | Visual microvascular and treatment response  |   | None  |
| Magnan et al. 2021 [54]           | Preserved segment (mean) compared to amputated rays***   |   | -   |
| Magnan et al. 2022 [55]           | Affected digits requiring amputation compared to historical group                              | 0 iloprost + HBO1<br>2 iloprost alone                                     | -   |
| Crooks et al. 2022 [56]           | Affected digits requiring amputation according to frostbite severity compared to standard care | Grade 2    Grade 3    Grade 4<br>0/44 (0%)    18/102 (18%)    44/96 (46%) | Tachycardia requiring dose reduction (12%), headache (8%), headache requiring iloprost discontinuation (4%)                     |

Close to U.S. frostbite population from published literature  
 Amputation for severe injury from 18-46% treated with iloprost

“.n” = information not available

\* Calculated using the total number of digits at risk minus number of digits amputated divided by total number of digits at risk multiplied by 100

\*\* Each phalanx and each metacarpal or metatarsal is defined as a segment. Preserved segments was defined as the difference between the number of segments with frostbite and lost segments

\*\*\* 4 segments comprise a ray (3 segments for the thumb or the hallux)



***Specific Aim 3: To evaluate the impact of thrombolytics (and iloprost) on early tissue salvage.***

# Antithrombotic: Anticoagulants & Antiplatelets

**TABLE 9-4 Frostbite Management: Drugs, Doses, and Modes of Action and Rationale\***

| Intervention              | Dose  | Action   |
|---------------------------|---|--|
| ★ Aspirin                 | 75-250 mg orally once daily   | Antiplatelet agent, improve rheology   |
| Ibuprofen                 | 400 mg bid or tid orally  | Antiprostaglandin effect   |
| Aloe vera gel or cream    | With dressing changes every 6 hr  | Topical antiprostaglandin effect   |
| Oxygen                    | 2 L/min above 4000 m (13,123 ft) or when SpO <sub>2</sub> is below 90%  | Improve tissue oxygenation   |
| Hyperbaric oxygen therapy | 2-2.5 atm 1-2 hr daily  | Improve tissue oxygenation; improve rheology                                       |
| Iloprost                  | 2-10 mg/hr IV titrated against side effects                             | Vasodilator; improve rheology  |
| Nitroglycerin             | 100 mcg IA single dose  | Vasodilator  |
| Papaverine                | 300 mg over 1 hr IA   | Vasodilator  |
| Reserpine                 | 0.1 to 0.25 mg once daily   | Vasodilator  |
| Buflomedil                | 400 mg IV or 300 mg bid orally  | Vasodilator; improve rheology  |
| Pentoxifylline            | 400 mg tid orally for 2-6 weeks   | Vasodilator; improve rheology  |
| 10% Dextran 40            | 20-mL bolus, 20 mL/hr IV  | Improve rheology   |
| t-PA                      | 1 mg/hr IA or IV  | Thrombolytic agent   |
| ★ LMW heparin             | Prophylactic dosage subcutaneously<br>Therapeutic dosage subcutaneously | DVT prevention; anticoagulant<br>Maintain patency of recently thrombolysed vessels |
| Tetanus prophylaxis       |   |  |

*bid*, Twice daily; *DVT*, deep vein thrombosis; *IA*, intraarterially; *IV*, intravenously; *LMW*, low-molecular-weight; *SpO<sub>2</sub>*, oxygen saturation as measured by pulse oximetry; *tid*, three times daily; *t-PA*, tissue plasminogen activator.

\*This table is intended to be used as a potential frostbite formulary reference, not as a protocol for treatment. See text for further discussion.

# Anti-inflammatory Agents – Ibuprofen

Effect on Frostbite: Ibuprofen inhibits COX enzymes reducing production of prostaglandins

Popularized in the 80's – confirmatory studies needed





Figure 1. Conversion of arachidonic acid to thromboxane and prostaglandins and their known analogues, inhibitors and roles (adapted from references 8, 22, 23 and 24).

Josianne Gauthier, Dunavan Morris-Janzen & Alexander Poole (2023) Iloprost for the treatment of frostbite: a scoping review, International Journal of Circumpolar Health, 82:1, 2189552, DOI: 10.1080/22423982.2023.2189552



# Cold injury and polytrauma



## National Inpatient Sample Frostbite patients (N=8085)

- crush injuries (1%)
- fractures (4%)
- intracranial hemorrhage (3.7%)
- other wounds (3.8%)



# Future

- Next year: first data from FROST multicenter study
  - tPA vs iloprost vs combination
  - Aspirin vs LMWH vs warfarin
  - Accuracy of visual assessment with perfusion imaging/grade
- Contact me if you'd like to participate in non-funded substudy evaluating frostbite injury at the extremes of age

Email: [Rachel.Nygaard@hcmcd.org](mailto:Rachel.Nygaard@hcmcd.org)  
[Frostbite.research@gmail.com](mailto:Frostbite.research@gmail.com)



My backyard 4/1/2023



# Hennepin Healthcare Department of Surgery



Cold ischemia time >> warm ischemia time

# Effect of Rapid and Prolonged Rewarming on Local Cold Injury<sup>(1)</sup>

Josef Pichotka, M. D.

Robert B. Lewis, Lieutenant Colonel, U. S. A. F. (MC)





Figure 1.—Distribution of changes in muscle weight in rapidly and slowly rewarmed legs with respect to the extent of necrosis. Solid triangles represent muscle weights of animals rapidly thawed after exposure to cold injury. Open triangles represent muscle weights of animals left to spontaneous rewarming in air.

# Complications associated with frostbite



Unplanned  
readmission  
N=842



Complications  
N=452 (53.7%)




Amputation



Non-healing  
wound



Infection or  
Cellulitis



# Revision Surgery



Frostbite  
13 (24%)



Debridement Alone  
5 (31%)

Amputation Alone  
6 (38%)

Both  
5 (31%)

Infection or Cellulitis  
6 (38%)

# Long-term outcomes



International Journal of  
Environmental Research  
and Public Health



Review

## Long-Term Sequelae of Frostbite—A Scoping Review

Ivo B. Regli <sup>1,2,\*</sup>, Giacomo Strapazzon <sup>1,3</sup>, Marika Falla <sup>1,4</sup>, Rosmarie Oberhammer <sup>5</sup> and Hermann Brugger <sup>1,3</sup>

<sup>1</sup> Institute of Mountain Emergency Medicine, Eurac Research, 39100 Bolzano, Italy; Giacomo.strapazzon@eurac.edu (G.S.); marika.falla@unitn.it (M.F.); Hermann.brugger@eurac.edu (H.B.)

<sup>2</sup> Department of Anaesthesia and Intensive Care, "F. Tappeiner" Hospital, 39012 Merano, Italy

<sup>3</sup> Department of Anaesthesia and Intensive Care, Medical University Innsbruck, 6020 Innsbruck, Austria

<sup>4</sup> Center for Mind/Brain Sciences, University of Trento, 38123 Rovereto, Italy

<sup>5</sup> Department of Anaesthesia and Intensive Care, Hospital of Brunico, 39031 Brunico, Italy; rosmarie.oberhammer@sabes.it

\* Correspondence: ivo.regli@eurac.edu; Tel.: +39-0471-055-863

Among 493 patients from five studies,  
341 (69%) had long term impairments.

| Article                     | Population and Follow Up Timing   | Frostbite Grade/Degree | Long-Term Sequelae   |
|-----------------------------|---|------------------------|--|
| Norheim et al., 2018 [15]   | Self-reported data of 397 Norwegian soldiers in 2017 having suffered frostbite from 2010–2014   | 1–2                    | 70 % with long-term sequelae<br>21% unable to work and undertake usual leisure activities  |
| Carlsson et al., 2014 [16]  | Self-reported data of 12 patients; 4 patients with hand frostbite, 6 patients with feet frostbite, and 2 patients with hand and feet frostbite; hand frostbite was followed-up after 4 month and 4 years, foot frostbite only after 4 years | 1–2                    | 4 months after frostbite of the hands (n = 6):<br>100% with discomfort when exposed to cold<br>67% with cold sensation<br>67% with white fingers/toes<br>4 years after frostbite of the hands (n = 6):<br>100% with discomfort when exposed to cold<br>83% with cold sensation<br>17% with white fingers/toes<br>4 years after frostbite of the feet (n = 8):<br>89% with discomfort when exposed to cold<br>100% with cold sensation<br>100% with white fingers/toes    |
| Koljonen et al., 2004 [17]  | Self-reported data form 14 patients with frostbite during the previous 7 years  | Not specified          | 15% with daily, intolerable pain<br>50% chronic pain<br>50% with limitations in their social life<br>36% with poor emotional well being  |
| Ervasti et al., 2000 [18]   | Clinical examination of 30 patients with frostbite 4–11 years earlier   | 2                      | 63% with sequelae of any kind<br>66% with increased tendency for vasospasm<br>53% with hypersensitivity to cold<br>40% with numbness of fingers<br>33% with declined sensitivity to touch<br>13% with lowered working ability  |
| Arvesen et al., 1996 * [19] | Clinical examination of 40 Norwegian soldiers with frostbite in the previous 21–78 months; 16 with involvement of the hands and 24 with involvement of the feet   | 1–3                    | 38% with disturbed sense of cold<br>38% with disturbed sense of heat<br>33% skin and nail dystrophias<br>20% with hyperhidrosis<br>18% with reduced light-touch perception<br>18% with reduced pain perceptions<br>10% with reduced blunt-touch perception<br>8% with pain on deep pressure<br>5% with paraesthesia<br>3% with reduced muscle power  |
| Rosen et al., 1991 * [20]   | Self-reported data of 40 Norwegian soldiers with frostbite at least 2 years prior; 18 with involvement of the hands and 28 with involvement of the feet   | 1–3                    | Hands:<br>100% with cold hypersensitivity<br>50% with paraesthesia<br>61% with hypaesthesia<br>56% skin and nail dystrophias<br>44% with pain<br>6% with hyperaesthesia<br>6% with hyperhidrosis<br>6% with arthralgia<br>Feet:<br>93% with cold hypersensitivity<br>64% skin and nail dystrophias<br>54% with pain<br>46% with paraesthesia<br>54% with hypaesthesia<br>14% with hyperhidrosis<br>11% with hyperaesthesia<br>7% pain when walking<br>4% with arthralgia |
| Taylor et al., 1989 [21]    | 40 US soldiers examined 6 months after frostbite  | 1–4                    | 65% with neurovascular sequelae (cold sensitivity, paraesthesia, pain, and hyperaesthesia)<br>8% had to be reassigned to new functions due to symptom severity   |
|                             |   |                        | Self-reported sequelae in winter<br>71% with numbness<br>70% with pain<br>69% with cold feet<br>58% with abnormal colour<br>53% with hyperhidrosis<br>40% with pathology in joints   |

# Objectives

- Understanding frostbite
- Best practices
- Outcomes
- Future studies

# Frostbite: a treatment guideline for prehospital treatment in a military environment

B L Turner,<sup>1</sup> T T.C.F van Dongen ,<sup>2,3</sup> R R Berendsen,<sup>4</sup> F J.M de Jong,<sup>1</sup> E L Endert,<sup>1</sup> R A van Hulst,<sup>5</sup> R Hoencamp<sup>2,3,6,7</sup>

## Box 1 : Prehospital care summarised

### 1a: Prolonged field care summarised:

- ⇒ Check for life-threatening disorders and treat these first
  - ⇒ Seek adequate shelter from the elements and prevent the victim from further cooling
  - ⇒ Remove constrictive objects like rings, etc
  - ⇒ Remove boots, change wet clothing. Keep in mind swelling may impair putting on boots later on
  - ⇒ If warm water is not directly available, attempt rewarming limb in armpit or groin of companion for 10 min. When not improving, severe frostbite is likely and rapid rewarming in water should be initiated as soon as possible
  - ⇒ In case of considerable risk of refreezing later; wrap affected limb in blanket and evacuate to base or medical facility
  - ⇒ Without risk of refreezing; immediately start rapid rewarming and adjunctive therapy.
  - ⇒ Start with ibuprofen, and if indicated give paracetamol as baseline analgesic with opioids as adjunctive therapy during rewarming limb
  - ⇒ Rehydrate patient with warm oral fluids (0.5–1 L; if sufficiently conscious)
  - ⇒ Evacuate to medical facility as soon as possible for further treatment
- DO NOT:

- ⇒ Apply emollients
- ⇒ Rub affected limb with hands or snow
- ⇒ Apply direct dry heat
- ⇒ Allow the patient to smoke

### 1b: Professional prehospital care summarised:

- ⇒ Check for life-threatening disorders and treat these first
- ⇒ Remove constrictive objects like rings, etc (if not done previously)
- ⇒ Place limb in warm water (37–42°C) until soft and red-purple colour reappears (usually 15–30 min)
- ⇒ Administer ibuprofen 400 mg orally every 8 hours
- ⇒ For pain control during rewarming consider administering opiates: fentanyl transmucosal lollypop (Netherlands Armed Forces), morphine intravenous (IV) or esketamine IV
- ⇒ For pain control after rewarming: give paracetamol 1 g orally every 6 hours (max 4 g/day), increase ibuprofen to max. 600 mg every 6 hours (max 2400 mg/day)
- ⇒ Rehydrate; if sufficiently conscious give 0.5–1 L warm oral fluids, or warmed (37–42°C) IV fluids in 250 mL boluses until urine production normalises
- ⇒ Consider nifedipine 30–60 mg/day in three to six doses or iloprost
- ⇒ Provide basic wound and blister care, be careful with haemorrhagic blisters (see DO NOT)
- ⇒ Apply topical aloe vera
- ⇒ Apply bulky dressing (not circumferential!) and elevate limb
- ⇒ Evacuate to definitive care as soon as possible (preferably <24 hours) for enhanced therapeutic interventions
- ⇒ Routine use of antibiotics is not recommended, consider tetanus prophylaxis when skin is damaged and tetanus status is unknown

### DO NOT:

- ⇒ Punctuate
- ⇒ Debride haemorrhagic blisters unless they are likely to rupture during transport to definitive care

## Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Frostbite: 2019 Update

Scott E. McIntosh, MD, MPH<sup>1</sup>; Luanne Freer, MD<sup>2,3</sup>; Colin K. Grissom, MD<sup>4</sup>; Paul S. Auerbach, MD, MS<sup>5</sup>; George W. Rodway, PhD, APRN<sup>6</sup>; Amalia Cochran, MD<sup>7</sup>; Gordon G. Giesbrecht, MD<sup>8</sup>; Marion McDevitt, DO, MPH<sup>9</sup>; Christopher H. Imray, MD<sup>10</sup>; Eric L. Johnson, MD<sup>11</sup>; Prativa Pandey, MD<sup>12</sup>; Jennifer Dow, MD<sup>13</sup>; Peter H. Hackett, MD<sup>14,15</sup>

**Table 1.** Summary of field treatment of frostbite (>2 h from definitive care)

### Treat hypothermia or serious trauma


1. Remove jewelry or other extraneous material from the body part.
2. Rapidly rewarm in water heated and maintained between 37 and 39°C (98.6 and 102.2°F) until area becomes soft and pliable to the touch (approximately 30 min); allow spontaneous or passive thawing if rapid rewarming is not possible.
3. Ibuprofen (12 mg · kg<sup>-1</sup> per day divided twice daily) if available.
4. Pain medication (eg, opiate) as needed.
5. Air dry (ie, do not rub at any point).
6. Protect from refreezing and direct trauma.
7. Apply topical aloe vera cream or gel if available.
8. Dry, bulky dressings.
9. Elevate the affected body part if possible.
10. Systemic hydration.
11. Avoid ambulation on thawed lower extremity (unless only distal toes are affected).

**Table 2.** Summary of initial hospital management of frostbite

1. Treat hypothermia or serious trauma.
2. Rapidly rewarm in water heated and maintained between 37 and 39°C (98.6 and 102.2°F) until area becomes soft and pliable to the touch (approximately 30 min).
3. Ibuprofen (12 mg · kg<sup>-1</sup> per day divided twice daily).
4. Pain medication (eg, opiate) as needed.
5. Tetanus prophylaxis.
6. Air dry (ie, do not rub at any point).
7. Debridement: selectively drain (eg, by needle aspiration) clear blisters and leave hemorrhagic blisters intact.
8. Topical aloe vera every 6 h with dressing changes.
9. Dry, bulky dressings.
10. Elevate the affected body part if possible.
11. Systemic hydration.
12. Thrombolytic therapy: consider for deep frostbite at the distal interphalangeal joint or proximal if less than 24 h after thawing; use angiography for prethrombolytic intervention and monitoring of progress. Consider intravenous thrombolysis if angiography is not available.
13. Iloprost therapy: consider for deep frostbite to or proximal to the proximal interphalangeal joint, within 48 h after injury, especially if angiography is not available or with contraindications to thrombolysis.
14. Clinical examination (plus angiography or technetium-99 bone scan if necessary) to assist determination of surgical margins. Evaluation by an experienced surgeon for possible intervention.



# Frostbite impact on the military



- Armed Forces Health Surveillance Division. Cold Weather Injuries Among the Active and Reserve Components of the U.S. Armed Forces, July 2018-June 2023. *MSMR*. 2023 Nov 20;30(11):2-11. PMID: 38051632.
- Armed Forces Health Surveillance Division. Update: Cold Weather Injuries, Active and Reserve Components, U.S. Armed Forces, July 2015-June 2020. *MSMR*. 2020 Nov;27(11):15-24.
- Endorf FW, Nygaard RM. Social Determinants of Poor Outcomes Following Frostbite Injury: A Study of the National Inpatient Sample. *J Burn Care Res*. 2021 Nov 24;42(6):1261-1265.

After rewarming

Imaging

Progression

Outcome

Case 1



Case 2



Case 3



After rewarming

Imaging

Progression

Outcome


Case 1



Case 2



Case 3



After rewarming

Imaging

Progression

Outcome


Case 1



Case 2



Case 3



# Supportive Cares

- Pharmacy
  - Ibuprofen - 600 mg TID with meals
  - Gabapentin - 300 mg TID
  - Lovenox therapeutic dose x 7 days post tPA
    - prophylactic dose while inpatient
    - Aspirin 81mg as outpatient
- PT/OT
  - Provide adaptive equipment
  - Active ROM and blocking exercises
- Wound cares (daily)
  - Baby soap and water
  - Topical aloe & Bacitracin
  - Conforming gauze & elastic flex netting
- Surgery
  - Debride and remove serous blisters
  - Small blisters (around ~1cm or less) without significant fluid, may be left intact regardless of their nature
  - Leave hemorrhagic blisters intact - debride after 72 hours